Concepts and Challenges of Biosimilars in Breast Cancer: The Emergence of Trastuzumab Biosimilars

• Váldodahkkit: Alina Uifălean (Dahkki), Maria Ilieş (Dahkki), Raul Nicoară (Dahkki), Lucia Maria Rus (Dahkki), Simona Codruţa Hegheş (Dahkki), Cristina-Adela Iuga (Dahkki)
• Materiálatiipa: Girji
• Almmustuhtton: MDPI AG, 2018-09-01T00:00:00Z.
• Fáttát: article
• Liŋkkat: Connect to this object online.

With the development of anti-human epidermal growth factor receptor 2 (HER2) monoclonal antibodies, trastuzumab-based therapy has become the standard of care among patients with early or advanced HER2-positive breast cancer. However, real-world data have shown that up to a half of patients do not re...